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Alpha (α)-asarone, a major effective component isolated from the Chinese medicinal herb
Acorus tatarinowii, is clinically used as medication for treating epilepsy, cough, bronchitis,
and asthma. In the present study, we demonstrated that α-asarone targets central nervous
system GABAA receptor as well as voltage-gated Na+ channels. Using whole-cell patch-
clamp recording, α-asarone inhibited spontaneous ﬁring of output neurons, mitral cells
(MCs), in mouse olfactory bulb brain slice preparation and hyperpolarized the membrane
potential of MCs.The inhibitory effect of α-asarone persisted in the presence of ionotropic
glutamate receptor blockers but was eliminated after adding a GABAA receptor blocker,
suggesting that GABAA receptors mediated the inhibition of MCs by α-asarone. This
hypothesis was supported by the ﬁnding that α-asarone evoked an outward current,
but did not inﬂuence inhibitory postsynaptic currents (IPSCs). In addition to inhibiting
spontaneous ﬁring, α-asarone also inhibited the Nav1.2 channel, a dominant rat brain Na+
channel subtype. The effects of α-asarone on a deﬁned Nav1.2 were characterized using
transfected cells that stably expressed the Nav1.2 channel isoform. α-Asarone displayed
strong tonic inhibition of Nav1.2 currents in a concentration- and membrane potential-
dependent fashion. α-Asarone reduced channel availability in steady-state inactivation
protocols by enhancing or stabilizing Na+ channel inactivation. Both Na+ channel blockade
and activation of GABAA receptors provide a possible mechanism for the known anti-
epileptic effects of α-asarone. It also suggests that α-asarone could beneﬁt patients with
cough possibly through inhibiting a Na+ channel subtype to inhibit peripheral and/or central
sensitization of cough reﬂexes.
Keywords: GABAA receptors, sodium channel blocker, α-asarone, central nerve Nav1.2 channel, olfactory bulb,
anticonvulsant, sensitization of cough reﬂexes
INTRODUCTION
Alpha (α)-asarone (1-propenyl-2,4,5-methoxybenzol; Figure 1),
a pharmacologically active component, is a natural product
that originates in Acorus tatarinowii Schott, A. calamus, and
in other plants (Dandiya and Menon, 1963; Hanson et al.,
2005; Björnstad et al., 2009; Wang et al., 2012). A. tatarinowii
is a Chinese herbal medicine which has been traditionally used
for centuries to treat respiratory diseases and neuronal dis-
orders such as epilepsy, cough, bronchitis, coma, and senile
dementia (Chinese Pharmacopoeia Committee, 2010; Gu et al.,
2010; Chen et al., 2013; Ni and Yu, 2013). The roots and
rhizomes of A. calamus are traditionally used for many men-
tal ailments (Dandiya and Menon, 1963) and for stomach
cramps, dysentery, asthma, bronchitis, cough, anthelmintic,
and as an insecticide (Mukherjee et al., 2007; Zuba and Byrska,
2012). In brief, these α-asarone containing herbs are heavily
used for the treatment of neuronal disorders and respiratory
diseases.
Several bioactivities of α-asarone have been reported recently,
e.g., reducing the level of lipids (Cassani-Galindo et al., 2005),
a neuroprotective effect (Limón et al., 2009) and reducing exci-
tatory synaptic activity (Gu et al., 2010). In China, α-asarone
is approved for the treatment of epilepsy, bronchitis, cough,
and asthma, indicating that it is effective in treating two dis-
orders, namely respiratory diseases and neuronal disorders in
clinical practice. The beneﬁcial effects of α-asarone on these
two unrelated disorders could suggest that α-asarone binds to
more than one protein target. The possible protein targets that
α-asarone binds to and the molecular mechanism(s) underlying
the distinct actions of α-asarone remain to be determined. It has
been reported that α-asarone prolonged the falling down latent
period of induced asthma and relaxed smooth muscle of tra-
chea by antagonizing histamine and acetylcholine. Recently, it was
reported that α-asarone alleviates epilepsy by modulating GABAA
receptors (Huang et al., 2013). Although potential mechanisms
underlying the anti-epileptic effect and the beneﬁcial effect for
respiratory diseases have been studied, the pharmacological bases
of these actions need to be further elucidated. Here, we hypoth-
esize that α-asarone binds to distinct disease-speciﬁc protein
targets to exert effects on both respiratory and neuronal disorders,
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FIGURE 1 | Chemical structure of α-asarone and methyleugenol
(4-allyl-1,2-dimethoxybenzene).
respectively. Alternatively, it binds to distinct protein targets of
one disorder and, thereby, displays synergistic effects for that
disorder.
Cough is a prominent symptom of respiratory disorders such
as chronic obstructive pulmonary disease, lung cancer, bronchitis,
and asthma. Persistent cough may be due to peripheral and/or
central sensitization of cough reﬂexes (Chung, 2002; Undem and
Carr, 2010). Primary afferent nerves are regarded as novel tar-
get for antitussive therapy (Undem and Carr, 2010; Muroi et al.,
2013; Spina and Page, 2013). Sodium channels play an impor-
tant role in the cough reﬂexes. This has been shown by the fact
that local anesthetics, blockers of sodium-dependent channels,
are inhibitors of the cough reﬂex (Chung, 2002; Spina and Page,
2013). Recently, in an effort to functionally screen thebioactivity of
a small group of natural products, we discovered that one of them,
methyleugenol, emerged as a novel sodium (Na+) channel blocker
(Wang et al., unpublished data). α-Asarone is a compound which
is similar to methyleugenol in its chemical structure (Figure 1).
Thus, we hypothesize that α-asarone may display similar func-
tional properties such as Na+ channel blockade to inhibit the
cough reﬂex.
α-Asarone has recently been shown to inhibit synaptically
driven-spiking of hippocampal neurons to exert an anti-epileptic
effect through activating GABAA receptors (Huang et al., 2013).
It is well known that many bioactive agents interact with more
than one therapeutic target protein. For example, several anticon-
vulsant agents such as valproic acid, gabapentin, and topiramate
have been shown to inhibit the function of Na+ channels and,
at the same time, activate GABAA receptors (Rho and Sankar,
1999). Felbamate andphenobarbital are anticonvulsant agents that
interact with both N-methyl-D-aspartate (NMDA) and GABAA
receptors (Rho et al., 1994; McNamara, 1996). The pharmacolog-
ical properties of these anticonvulsant agents suggest that an ideal
anticonvulsant agent could target two or more epilepsy-related
proteins or ion channels to control neural hyperexcitability. Thus,
α-asarone may possibly interact with more than one therapeu-
tic protein to exert its anti-epileptic effects. In central nervous
system (CNS), voltage-gated type II/IIA Na+ channels (Nav1.2A)
are preferentially localized in axons (Westenbroek et al., 1989).
The tetrodotoxin (TTX)-sensitive channel isoform Nav1.2A has
been studied as the target of multiple anti-epileptics and the
inhibition of Nav1.2A is considered as an anticonvulsant mech-
anism (Ragsdale et al., 1991; Dupere et al., 1999). Therefore,
based on the chemical similarity of α-asarone to methyleugenol,
Nav1.2 is a good candidate to explore its possible regulation by
α-asarone.
Epileptic seizures result from poorly controlled neuronal activ-
ity at a seizure focus and the subsequent spread of electrical
excitation in brain circuits (Rall and Schleifer, 1990). It is not
surprising thatmost effective anti-seizuremedications inhibit neu-
ronal excitability by modulating the function of several types of
proteins such as Na+ channels, NMDA receptors, and GABA
receptors (Rho and Sankar, 1999). Output neurons such as mitral
cells (MCs) in the mouse main olfactory bulb (MOB) display their
neuronal activity as spontaneous action potential ﬁring, which
can be modulated by intrinsic membrane receptors as well as
synaptic inputs (Shepherd et al., 2004; Ennis et al., 2007; Wang
et al., 2011). In the rodent MOB, MCs express high levels of
different receptors such as GABA receptors (GABAA, GABAB),
ionotropic andmetabotropic glutamate receptors (NMDA,AMPA,
metabotropic glutamate receptor 1 (mGluR1), kainite). Most
of these receptor proteins are thought to be epilepsy-related
(McNamara, 1996; Snell et al., 2000; Wang et al., 2002; Ennis et al.,
2007). Therefore, compared to the synaptically driven-ﬁring neu-
rons (Huang et al., 2013), spontaneous ﬁring MCs is a better
choice for exploring the possible regulation of neuronal excite-
ment by α-asarone. In this study, we used acute slices of the mouse
MOB as well as stably transfected cells expressing the Nav1.2
channel α-subunit to determine the potential cellular targets of
α-asarone.
MATERIALS AND METHODS
CELL CULTURE
The CNaIIA cell line (gift from Dr. W.A. Catterall) was derived
from a Chinese hamster ovary (CHO-K1) cell line stably trans-
fected with a cDNA encoding the rat brain type IIA Na+ channel
(Nav1.2A; Ragsdale et al., 1991; Scheuer et al., 1992). CNaIIA cells
were cultured inRoswell ParkMemorial Institutemedium (Gibco)
with 5% fetal bovine serum, and 100 μg/ml streptomycin and
100 U/ml penicillin. G418 (400 μg/ml) was included to select for
transfectants. Then the cells were passed and plated on glass cov-
erslips in 35-mm dishes in a 5% CO2 atmosphere at 37◦C for 1–3
days before experimentation.
WHOLE-CELL VOLTAGE-CLAMP RECORDING FROM TRANSFECTED CHO
CELLS
Na+ currents were recorded using the whole-cell patch clamp
recording technique (Hamill et al., 1981). The cultured cells on
coverslips were transferred to a handmade recording chamber
and continuously perfused at room temperature with extracel-
lular solution containing (in mM): 130 NaCl, 4 KCl, 1.5 CaCl2,
1.5 MgCl2, 5 glucose, 5 HEPES, 20 sucrose, pH 7.4 adjusted
with NaOH. The recording chamber volume was approximately
0.4 ml and the ﬂow rate was 0.6 ml/min. MP-285 microma-
nipulator (Sutter Instrument Co., Novato, CA, USA) was used
to place the electrode onto the cell. Patch pipettes were pulled
from borosilicate glass capillaries (Drummond Scientiﬁc Co.,
Broomall, PA, USA) on an electrode puller (Model P-97, Sutter
Instrument Co.) and were ﬁlled with a 0.2 μm ﬁltered inter-
nal solution containing (in mM): 90 CsF, 60 CsCl, 10 NaCl, 5
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HEPES, pH 7.4 adjusted with NaOH. The pipettes had input
resistance of 0.8–1.4 M. Recordings were performed at room
temperature (22◦C) with a patch clamp EPC 9 (HEKA Elek-
tronik GmbH, Germany) and were ﬁltered at 5 kHz. Leakage
currents were subtracted using a P/4 or P/2 protocol. Pulse (HEKA
Elektronik) was used for experimental control and basic data
analysis.
The methods of recording Na+ currents from Nav1.2 express-
ing cells were similar to our previous report (Wang et al., 2002).
Cellswith series resistance of less than 2.5Mwere used for drug test
experiments. Only cells with whole cell maximal Na+ currents of
at least 1 nA were used in the analysis. Na+ currents recorded from
Nav1.2A expressing cells always increased progressively within
the ﬁrst 20 min after establishing the whole-cell-recording con-
ﬁguration and then were relatively stable. Thus, drugs were
applied only during this period (after 20 min), especially for test-
ing tonic inhibition evoked by the drug. Time-dependent shifts
(∼0.5 mV before and after perfusion) in the inactivation curve
of Nav1.2 have not been considered in calculating the shift by
drug.
SLICE PREPARATION
Wild type mice (C57BL/6J, Jackson Laboratory, Bar Harbor, ME,
USA) were used in agreement with Institutional Animal Care and
Use Committee and NIH guidelines. Juvenile (16- to 25-day old)
mice were decapitated, and the MOBs were dissected out and
immersed in artiﬁcial cerebrospinal ﬂuid (ACSF, see below) at
4◦C, as previously described (Heinbockel et al., 2004). Horizontal
slices (400 μm-thick) were cut parallel to the long axis using a
vibratome (Vibratome Series 1000, Ted Pella Inc., Redding, CA,
USA). After 30 min at 30◦C, slices were incubated in a holding
bath at room temperature (22◦C) until use. For recording, a brain
slice was placed in a recording chamber mounted on a micro-
scope stage and maintained at 30 ± 0.5◦C by superfusion with
oxygenated ACSF ﬂowing at 2.5–3 ml/min.
SLICE RECORDING AND DATA ACQUISITION
Visually guided recordings were obtained from cells in the MC
layer with near-infrared differential interference contrast optics
and a BX51WI microscope (Olympus Optical, Tokyo, Japan)
equipped with a camera (C2400-07, Hamamatsu Photonics,
Japan). Images were displayed on a Sony trinitron color video
monitor (PVM-1353MD, Sony Corp. Japan). Recording pipettes
(5–8 M) were pulled on a Flaming-Brown P-97 puller (Sutter
Instrument Co.) from 1.5 mm O.D. borosilicate glass with ﬁla-
ment. Seal resistance was routinely >1 G and liquid junction
potential was 9–10 mV; reported measurements were not cor-
rected for this potential. Data were obtained using a Multiclamp
700B ampliﬁer (Molecular Devices, Sunnyvale, CA, USA). Signals
were low-pass Bessel ﬁltered at 2 kHz and digitized on computer
disk (Clampex 10.1, Molecular Devices). Data were also collected
through a Digidata 1440A Interface (Molecular Devices) and dig-
itized at 10 kHz. Holding currents were generated under control
of the Multiclamp 700B Commander.
The ACSF consisted of (in mM): NaCl 124, KCl 3, CaCl2 2,
MgSO4 1.3, glucose 10, sucrose NaHCO3 26, NaH2PO4 1.25
(pH 7.4, 300 mOsm), saturated with 95 O2/5% CO2 (modiﬁed
from Heyward et al., 2001). The standard pipette-ﬁlling solu-
tion consisted of (mM) K gluconate 125, MgCl2 2, HEPES 10,
Mg2ATP 2, Na3GTP 0.2, NaCl 1, EGTA 0.2. The ACSF consisted
of the following (in mM): 124 NaCl, 3 KCl, 2 CaCl2, 1.3 MgSO4,
10 glucose, 4.4 sucrose, 26 NaHCO3, 1.25 NaH2PO4 (pH 7.4,
300 mOsm), saturated with 95% O2/5% CO2. For intracellular
recording of spiking activity, the pipette-ﬁlling solution consisted
of the following (in mM): 144 K-gluconate, 2 MgCl2, 10 HEPES, 5
Mg2ATP, 0.5 Na3GTP, 2 NaCl, 0.2 EGTA. Low-Cl−-based pipette
solution contained the following (in mM): 125 cesium methane-
sulfonate (CsMeSO3), 1 NaCl, 10 phosphocreatine di–tris salt, 5
ATP, 0.5 GTP, 0.5 EGTA, 10 HEPES, 10 QX-314 [2(triethylamino)-
N-(2,6-dimethylphenyl) bromide], pH 7.3 with 1 N CsOH
(290 mOsm). High-Cl−-based pipette solution contained the fol-
lowing (in mM): 110 cesium chloride, 10 tetraethylammonium–
Cl, 2 NaCl, 10 phosphocreatine di–tris salt, 5 ATP, 0.5 GTP,
0.5 EGTA, 10 HEPES, 10 QX-314, pH 7.3 with 1 N CsOH
(290 mOsm).
CHEMICALS AND DRUG APPLICATION
For all experiments, drugs were bath perfused at the ﬁnal con-
centrations indicated by dissolving aliquots of stock solution in
ACSF or in extracellular solution. α-Asarone was supplied by
the National Institute for the Control of Pharmaceutical and
Biological Products (Beijing, China). Stock solution of 40 mM
α-asarone was prepared in dimethyl sulfoxide (DMSO) and then
diluted to the desired concentrations for experiments (ﬁnal con-
centration of DMSO in bath < 0.1%). The following drugs
were also bath applied: L-2-amino-5-phosphonopentanoic acid
(AP5, APV), 6-cyano-7-nitroquinoxaline-2-3-dione (CNQX), 2-
(3-carboxypropyl)-3-amino-6-(4 methoxyphenyl)-pyridazinium
bromide (gabazine, SR-95531). Chemicals were supplied by Tocris
(Ellisville, MO). Control recordings showed that 0.1% DMSO
had no detectable effects on MC activity and the Na+ currents
in transfected CHO cells.
DATA ANALYSIS
The data obtained with cultured CHO cells were analyzed using
a combination of PulseFit (HEKA Elektronik) and SigmaPlot
9.0 (Jandel Scientiﬁc, Corte Madera, CA, USA) software. The
data obtained with slice recordings were analyzed using a com-
bination of Clampﬁt 10.2 (Molecular Devices) and Origin8
(OriginLab Corporation, Northampton, MA, USA). All results
are presented as the mean SEM. Tests for statistical sig-
niﬁcance were performed using paired Student’s t-tests, and
one-way ANOVA followed by the Bonferroni test for multiple
comparisons.
RESULTS
In culture preparations, 20–30% of Nav1.2 cells displayed fast,
transient inward currents following depolarization. The maximal
peak inward currents of Nav1.2 ranged from 0.7 to 8 nA. How-
ever, in a few cells, it went up to 20 nA. These currents were
blocked completely by 0.5 μM TTX, conﬁrming their identity
as uncontaminated Na+ currents under these recording con-
ditions. In slices, MCs were identiﬁed visually by their soma
location and relatively large soma size, and by their input resistance
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(297 ± 19.2 M, n = 46). Spontaneous ﬁring is an intrinsic
property of MCs (Ennis et al., 2007).
α-ASARONE TONICALLY INHIBITED RAT BRAIN Nav1.2 CURRENTS
A speciﬁc Na+ channel subtype (Nav1.2) is known to be dominant
in the rat brain (Westenbroek et al., 1989). To determine whether
α-asarone directly interacted with central nervous Na+ channels,
we subjected the drug to procedures similar to those used for
phenytoin and carbamazepine (CBZ) characterization (Ragsdale
et al., 1991).
Bath application of α-asarone reversibly reduced the ampli-
tude of the Nav1.2 peak currents (Figure 2). The currents of
Nav1.2 shown in Figure 2A were elicited by stepping to vari-
ous depolarized potentials from a holding potential of −100 mV.
Figure 2B shows the current–voltage (I–V) relationship of Nav1.2
channels in control and in various concentrations of α-asarone,
indicating that α-asarone inhibited Na+ currents. The shape of
the I–V curve was unaffected by concentrations of α-asarone, sug-
gesting that α-asarone, at the concentrations tested, had no effect
on the voltage-dependent activation of Na+ channels, which was
further analyzed in Figure 3. In Figure 2C, the currents were
elicited by stepping to 0 mV from a holding potential of −100 mV,
demonstrating that the tonic inhibition of Nav1.2 channels by α-
asarone was concentration-dependent. Figure 2D shows the tonic
inhibition by α-asarone on Nav1.2 currents which was determined
by measuring concentration–response relationships at −100, and
−60 mV holding potentials, respectively. At −100 mV, almost all
channels were in the resting state which was observed by mea-
suring the inactivation curve of Nav1.2 (shown in Figure 3). At
−60 mV holding potential, about 15% of the channels were in the
inactivated state. The averaged inhibition evoked by α-asarone at
varying concentrations was well ﬁt to the Hill equation. Based on
FIGURE 2 | (A–D)Tonic inhibition of α-asarone on Nav1.2 channels. (A)The
current traces of Nav1.2 illustrate the current–voltage (I–V) relationship of the
channel. (B)The I–V relationships in control and in the presence of various
concentrations of asarone. The currents were elicited by stepping to various
depolarized potentials (ranging from – 80 to +100 mV in 10-mV increments)
for 9 ms, and then returning to the holding potential of –100 mV. Peak
currents at each depolarized potential were measured. The data are from a
representative cell. (C) Superimposed current traces recorded before
(control), during the application of 20 μM, 500 μM, and 2 mM α-asarone. The
currents were recorded from the same cell and were elicited by a 10-ms
pulse to 0 mV from the −100 mV holding potential. (D) Concentration–
response curves for the inhibition of Na+ currents by α-asarone at different
holding potentials. The cells were held at –100 mV, and –60 mV, respectively,
and stepped to 0 mV for 10 ms. The peak currents in the presence of asarone
were normalized to the corresponding control peak currents, and then
averaged. Each point was the mean ± SEM of 4–6 cells. The lines are best ﬁts
for data to the Hill equation: y = 1 − xn/(Knd + xn), where y is the fractional
current, K d is the apparent dissociation constant for asarone, and n is the Hill
coefﬁcient. K d and n were estimated using a Marquadt non-linear
least-squares routine.
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FIGURE 3 | Effects of α-asarone on voltage-dependent availability and
activation of Nav1.2 channels.The shift of inactivation curves of Nav1.2
channels by 500 μM asarone (n = 5). The voltage dependence of
steady-state inactivation (h∞) was examined by applying 500-ms prepulse
potentials from –120 to 10 mV in 10-mV increments from a holding
potential of –100 mV before stepping to the test potential (0 mV) for 35 ms.
The peak current (I) for each cell was normalized with respect to the ﬁrst
value measured at test potential (0 mV). Conductance–voltage relationship:
from the peak Na+ currents obtained in Figures 2A,B, the Na+
conductance values (G) in the absence and presence of 500 μM α-asarone
were calculated, normalized to the maximum in control, and plotted as a
function of membrane potentials (V ). The smooth curves through the data
are drawn according to the equation: y = 1/1 − exp[(V − V h)/k ]. Where
V = membrane potential, V h = the prepulse potential where the current is
half-maximal, and k = the slope factor.
a ﬁtted Hill coefﬁcient (n) value of 1.2 at a holding potential of
−60 mV, it appeared that the stoichiometry of drug and receptor
interaction was 1:1. The estimation of IC50 value obtained by ﬁt
to the Hill equation was 913 μM at −100 mV, and 217 μM at
−60 mV, respectively. The result indicates that α-asarone exhib-
ited a much higher afﬁnity for channels at the −60 mV holding
potential, where a subset of channels was in the inactivated
state.
α-ASARONE SHIFTED THE STEADY-STATE INACTIVATION CURVE
Na+ channel blockers like CBZ and phenytoin have voltage-
dependent effects on the availability of Na+ currents, as seen
by a shift of the steady-state inactivation curve to more nega-
tive potentials (Schwartz et al., 1989; Ragsdale et al., 1991). The
steady-state inactivation (h∞) curve was examined to elucidate
the effects of α-asarone on the voltage-dependent availability of
Nav1.2 channels.
α-Asarone displayed voltage-dependent effects on the avail-
ability of Nav1.2 current. It shifted inactivation curves toward
more negative potentials (Figure 3). The currents for each cell
were normalized and averaged, and then ﬁt to a single Boltz-
mann relationship from which the mean Vh and k values were
calculated. The slope factors (k) of the curves were not affected
at the concentrations of α-asarone we tested. The results suggest
that α-asarone might interact preferentially with the inactivated
state of the channels, which is typically found at depolarized
potentials.
α-ASARONE SUPPRESSED SPONTANEOUS SPIKING OF MITRAL CELLS
AND HYPERPOLARIZED THEIR MEMBRANE POTENTIAL
The above results indicate that α-asarone acts on Na+ channels.
In addition to Na+ channels, α-asarone may interact with other
target proteins that are of clinical importance. MCs are output
neurons in the MOB and spontaneously generate action poten-
tials which can be modulated by intrinsic membrane properties
as well as synaptic inputs (Shepherd et al., 2004; Ennis et al., 2007;
Wang et al., 2011). We used the intrinsic properties of MCs such
as spontaneous ﬁring, membrane potential, and membrane con-
ductance to evaluate the effect of α-asarone on neuronal activity
and to determine the possible molecular mechanisms underlying
the effects.
Bath application of α-asarone modulated the spiking rate
of MCs (Figure 4). Compared to control conditions, 20 μM
α-asarone signiﬁcantly reduced the MC ﬁring rate. α-Asarone
reversibly decreased MC ﬁring rate from 4.7 ± 0.5 Hz to
2.9 ± 0.5 Hz (n = 9; p < 0.0001, paired t-test). The reduction
of ﬁring rate was accompanied by a hyperpolarization of the MC
membrane potential from −50.8 ± 1.2 to −52.3 ± 1.2 mV (n = 8;
p < 0.001, paired t-test). Figure 4 illustrates the inhibitory effect
of α-asarone in an original recording from a typical MC.
GABAA RECEPTORS RATHER THAN IONOTROPIC GLUTAMATE
RECEPTORS WERE INVOLVED IN THE α-ASARONE-INDUCED
INHIBITION OF NEURONAL EXCITABILITY
Ionotropic glutamate receptors play a critical role in the regulation
of neuronal excitability in the MOB (Ennis et al., 2007). Blockade
of ionotropic glutamate receptors can result in neuronal inhi-
bition. We examined the effects of α-asarone-induced neuronal
inhibition in the presence of AMPA/kainate and NMDA receptor
blockers.
In the presence of CNQX (10 μM, a potent AMPA/kainate
receptor antagonist) and D-AP5 (50 μM, a potent NMDA recep-
tor antagonist), the inhibitory effects of α-asarone persisted as
seen by a reduction of the ﬁring rate (in CNQX + D-AP5:
4.2 ± 0.6 Hz; in CNQX, D-AP5 plus α-asarone: 3.1 ± 0.5 Hz;
n = 5; p < 0.01, paired t-test), and membrane hyperpolariza-
tion of MCs by −1.4 ± 0.2 mV (n = 5; p < 0.01, paired t-test;
Figure 5A). In comparison with the results shown in Figure 4,
these data indicate that CNQX plus D-AP5 had no any additional
FIGURE 4 | α-asarone suppressed the spiking activity of MCs. Original
recording from a representative MC. Bath application of α-asarone reduced
the ﬁring rate and hyperpolarized the membrane potential. The arrow
indicates the initial level of the resting potential.
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FIGURE 5 | (A–C) A GABAA receptor antagonist rather than AMPA/kainate
or NMDA receptor antagonists blocked the α-asarone-induced inhibition of
MCs. (A) Original recording obtained from a MC shows that
α-asarone-induced suppression of neuronal ﬁring recorded in a
representative MC in the presence of iontropic glutamate receptor
antagonists CNQX and D-AP5. (B) Current trace shows that α-asarone
failed to evoke the inhibitory effects in the presence of fast synaptic
blockers. (C) In gabazine, a GABAA receptor antagonist, the ﬁring rate
remained the same. Current trace shows that gabazine eliminated the
inhibitory effects of α-asarone.
effect on α-asarone-induced suppression of MC activity (p > 0.05;
ANOVA and Bonferroni post hoc analysis).
Even though the asarone-evoked inhibitory effects persisted
in the presence of ionotropic glutamate receptor blockers, the
inhibition was prevented by the application of synaptic block-
ers that contained both ionotropic glutamate receptor block-
ers and a GABAA receptor blocker (synaptic blockers; CNQX,
10 μM; AP5, 50 μM; gabazine, 5 μM; Figure 5B). In synap-
tic blockers, α-asarone failed to reduce the ﬁring rate of MC
cells (in syn. blockers: 4.8 ± 0.9 Hz; in syn. blockers plus
α-asarone: 4.8 ± 0.9 Hz; n = 5, p > 0.05, paired t-test), indi-
cating GABAA receptor may mediate the inhibitory effect of
α-asarone.
To further examine the role of GABAA receptors in α-asarone-
evoked inhibition, the effect of α-asarone was measured during
GABAA receptor blockade. Blockade of GABAA receptors can
result in excitation or disinhibition of neurons. In the presence
of gabazine, the inhibition of MC activity by α-asarone was
eliminated (in gabazine: 5.3 ± 1.0 Hz; in gabazine plus α-asarone:
5.2 ± 1.0 Hz; n = 6, p > 0.05, paired t-test; Figure 5C). These
results indicate that GABAA receptors rather than ionotropic
glutamate receptors were involved in the α-asarone-evoked inhi-
bition of MC activity.
GABAA receptors are present on MC dendrites in the MC
layer of the MOB and play an important role in regulating MC
excitability by suppressing neuronal activity (Laurie et al., 1992;
Shepherd et al., 2004; Panzanelli et al., 2005). Bath application of
γ-aminobutyric acid (GABA; 50 μM) dramatically decreased the
ﬁring rate of MCs (in control: 5.0± 0.8Hz; inGABA: 1.7± 0.3Hz;
n = 6; p < 0.001, paired t-test) and hyperpolarized MCs by
−1.1 ± 0.3 mV (n = 6; p < 0.05, paired t-test). The potent inhi-
bition by GABA is consistent with previous reports showing that
GABA receptors are abundant in MCs (Laurie et al., 1992; Persohn
et al., 1992; Panzanelli et al., 2005).
Further evidence for the involvement of GABAA receptors
came from measurements of MC ionic currents induced by α-
asarone. In whole-cell voltage clamp recording mode with Na+
channel blocker QX-314 included in the pipette solution, 20 μM
α-asarone evoked an outward current in MCs of 11.8 ± 2.1 pA
(n= 10; range 2.0–17 pA). The steady-state currents at the holding
potential in α-asarone were measured and subtracted from that in
ACSF (Figure 6). In the presence of gabazine, α-asarone-induced
FIGURE 6 | α-Asarone induced outward currents in MCs. (A) Original
recording from a MC illustrates an outward current induced by 20 μM
α-asarone. Low-Cl− pipette solution containing sodium channel blocker
QX-314 was used, and holding potential is 0 mV. (B) α-Asarone induced an
outward current in MC with high-Cl− pipette solution containing QX-314.
Holding potential is at −60 mV. sIPSCs appear as downward deﬂections.
The dotted green lines indicate the zero-current baselines.
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outward currents were blocked (−0.3 ± 1.5 pA, n = 4; the cur-
rents in α-asarone plus gabazine was subtracted from that in
gabazine).
The gabazine-mediated blockade of α-asarone-evoked inhi-
bition of MCs suggests that α-asarone either binds to GABAA
receptors to generate the inhibitory effects or it enhances extra-
cellular GABA levels. α-Asarone-evoked outward currents may
result from an enhancement of GABA release. This hypothe-
sis was not supported by our observation that α-asarone was
not able to increase the frequency of spontaneous inhibitory
postsynaptic currents (sIPSCs) in MCs (Figure 6), suggesting
that α-asarone enhanced tonic GABAergic inhibition rather than
phasic GABAergic inhibition. With the recording conditions of
Figure 6A, sIPSCs were upward and exhibited some rundown.
Thus, a high-Cl− pipette solution was used for sIPSCs record-
ings in subsequent experiments. In conditions of a high-Cl−
pipette solution (containing QX-314), the sIPSCs were down-
ward deﬂected. α-Asarone induced an outward current as seen
in Figure 6B, but did not change the frequency of sIPSCs (in
control: 2.3 ± 0.3 Hz; in α-asarone: 2.4 ± 0.4 Hz) (n = 7;
p > 0.05, paired t-test). The sIPSCs were completely eliminated
by gabazine, indicating that sIPSCs were mediated by GABA act-
ing on GABAA receptors. In the presence of Na+ channel blocker
(QX-314), α-asarone induced outward currents in MCs, but did
not signiﬁcantly alter sIPSC frequency, suggesting that asarone-
evoked inhibition ismediatedbydirect actiononGABAA receptors
rather thanby indirect action through the elevationof tissueGABA
levels.
DISCUSSION
In the present study, we showed that α-asarone has a dual effect
on neuronal proteins. It inhibited spontaneous activity of out-
put neurons through activation of GABAA receptors in the MOB
and it inhibited voltage-gated Na+ currents of the rat brain Na+
channel α-subtype (Nav1.2). Our study shows that α-asarone
markedly inhibited Na+ currents of Nav1.2, which are known
to be dominant in the rat brain, in a concentration and membrane
potential-dependent manner. α-Asarone reduced the availability
of Na+ channels in steady-state inactivation protocols by enhanc-
ing or stabilizing Na+ channel inactivation. In addition to the
blockade of Na+ channels, α-asarone inhibited neuronal activ-
ity of MCs. Ionotropic glutamate receptors were not involved
in α-asarone-evoked inhibition of neuronal activity. Instead,
α-asarone-evokedneuronal inhibitionwasmediated bydirect acti-
vation of GABAA receptors in the MOB rather than by increasing
GABA release from GABAergic interneurons, suggesting the non-
synaptic GABAA receptors might be responsible for the effect
of α-asarone inhibition. Therefore, we identiﬁed both GABAA
receptors and voltage-activated Na+ channels as cellular targets of
α-asarone.
α-Asarone inhibits synaptically driven spiking in hippocam-
pal neurons (Huang et al., 2013). Spiking in these hippocampal
neurons is driven by glutamate and can be blocked by an AMPA
receptor antagonist (Huang et al., 2013). The principal neurons in
MOB are anatomically and functionally different from hippocam-
pal neurons. MCs in the MOB are output neurons and exhibit
their neuronal activity as spontaneous action potential ﬁring,
which can be modulated through intrinsic membrane properties
as well as synaptic inputs (Shepherd et al., 2004; Ennis et al., 2007).
Here, we found that α-asarone inhibited spontaneous, intrinsic
spiking of MCs through activation of GABAA receptors. Thus,
α-asarone can inhibit both synaptically driven spiking and intrin-
sic spiking in mouse neurons, possibly to exert the anti-epileptic
effects.
α-Asarone interacted directly with Na+ channels. Since Na+
channel blockers are often able to suppress sustained repetitive ﬁr-
ing of neurons as use-dependent inhibition, we tested the effect
of α-asarone on sustained repetitive ﬁring of MCs in the pres-
ence of 5 μM gabazine (gabazine was used to block the action
of α-asarone on GABAA receptors). By injecting 100, 200 and
400 pA currents (500 ms) to depolarize MCs, the frequency of
ﬁring during the current injection was measured in the presence
and absence of α-asarone. Unexpectedly, we did not see a sig-
niﬁcant reduction of ﬁring rate by α-asarone (data not shown;
only two out of 14 cells displayed the inhibition by 20 μM and
40 μM α-asarone on sustained repetitive ﬁring). We are not
sure why α-asarone did not show blockade of action potential
in our recording condition. It is possible that the concentrations
of α-asarone we used are not high enough to block ﬁring. The
failure of blocking ﬁring at tested concentrations implies that
Na channels may not contribute the a-asrarone-induced inhi-
bition at the concentration of 20 and 40 μM. However, we do
ﬁnd use-dependent inhibition by 40 μM α-asarone in expressed
CHO cell (data is not shown). Since α-asarone is a Na+ chan-
nel blocker, how can it fail to suppress sustained ﬁring? Several
scenarios might explain the lack of α-asarone effect on sustained
ﬁring. Firstly, increased input resistance (Ri) are observed with
GABAA blockers (data not shown). The increased Ri by GABAA
blockers might partly explain the lack of effect of α-asarone on
ﬁring rate. Secondly, it is well known that a substantial pro-
portion of patients with chronic epilepsy (up to 30%) remain
refractory to antiepileptic drugs, i.e., not all neuronal activity
at a seizure focus and the subsequent spread of electrical exci-
tation in brain circuits can be well controlled by antiepileptic
drugs including Na+ channels blockers. Possibly, Na+ channels
blockers such as anticonvulsant CBZ may not be able to sup-
press epileptic-like activity in some speciﬁc area in the brain such
as MOB. Thirdly, it has been reported that the action of the
CBZ on Na+ channel appears to depend on the presence of the
accessory β1 Na+ channel subunit (Kazen-Gillespie et al., 2000).
The involvement of the β1 subunit in drug–Na+ channel inter-
actions was shown by the fact that functional loss of accessory
Na+ channel subunits is a feature of a number of neurological
disorders, including epilepsy (Gastaldi et al., 1998; Ellerkmann
et al., 2003; Patino et al., 2009; Uebachs et al., 2012). Na+ chan-
nel α- and β-subunit mRNAs exhibit differential expression in
the CNS, suggesting that the subtypes have distinct physiological
roles and contribute to the functional heterogeneity of neurons
in the CNS (Whitaker et al., 2000, 2001). A localization study
of Na+ channel β1 and β2 mRNA in the CNS demonstrates
a differential expression in different neurons (Oh et al., 1994;
Levy-Mozziconacci et al., 1998). It will be interesting to deter-
mine if accessory β1 or β2 subunits are functionally expressed in
MCs. Fourthly, Na+ channel blockers such as eugenol have been
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reported to inhibit Na+ currents that are not dependent on the
stimulus frequency in rat dorsal root ganglion neurons (Cho et al.,
2008). It remains to be tested if commonly used Na+ channel
blockers such as CBZ and phenytoin can effectively suppress sus-
tained ﬁring of MCs in the MOB. In the meantime, there is no
report showing that anticonvulsants such as CBZ cause partial
loss of olfaction. Since MCs are principal neurons in the MOB, the
reduction/blockade of spontaneous ﬁring of MCs may alter odor
processing.
Persistent cough may be due to peripheral and/or central sensi-
tization of cough reﬂexes (Chung, 2005; Undem and Carr, 2010).
The primary afferent nerves are regarded as novel target for anti-
tussive therapy (Undem and Carr, 2010; Muroi et al., 2013; Spina
and Page, 2013). Lidocaine, a local anesthetic that acts by blocking
Na+ channels, is an inhibitor of the cough reﬂex (Chung, 2002;
Spina and Page, 2013). It is possible that α-asarone may exert
its antitussive effect as a Na+ channel blocker to inhibit cough
reﬂexes. Thus, our ﬁndings provide a possible mechanism under-
lying the effects of α-asarone on cough which is a prominent
symptom of bronchitis, asthma, chronic obstructive pulmonary
disease, and lung cancer. We identiﬁed both GABAA receptors and
voltage-activated Na+ channels as cellular targets of α-asarone.
These cellular targets might be of therapeutic relevance in the
treatment of both epilepsy and respiratory diseases. The precise
mechanism by which α-asarone inhibits cough reﬂexes in animal
models or humans remains to be elucidated.
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